Dexamethasone use in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate:this“cort”is not out of order!

作     者：Charles Van Praet Valérie Fonteyne Nicolaas Lumen 

作者机构：Department of UrologyGhent University HospitalGhent 9000Belgium Department of Radiation OncologyGhent University HospitalGhent 9000Belgium 

出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)

年 卷 期：2022年第24卷第2期

页      面：225-225页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：patients acetate metastatic 

摘      要：In the recent issue of Asian Journal of Andrology,Ni et al.1 explore a therapeutic reflex that we as clinicians have developed over the years when treating patients with metastatic castration-resistant prostate cancer(mCRPC)with abiraterone acetate(AA).With the first signs of progression,usually,this is a rising prostate-specific antigen(PSA)level;we often continue AA but switch corticoid from prednisone to 0.5 mg of dexamethasone *** a subset of patients,this causes a temporary PSA decline lasting several months to occasionally over a *** is a very cheap,well-tolerated,and safe option,although evidence for a long-term oncological benefit,such as an overall survival(OS)increase,is lacking.